{"id":52701,"date":"2026-01-04T14:54:09","date_gmt":"2026-01-04T06:54:09","guid":{"rendered":"https:\/\/flcube.com\/?p=52701"},"modified":"2026-01-04T14:54:10","modified_gmt":"2026-01-04T06:54:10","slug":"genmab-discontinues-acasunlimab-to-focus-on-late-stage-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52701","title":{"rendered":"Genmab Discontinues Acasunlimab to Focus on Late\u2011Stage Portfolio"},"content":{"rendered":"\n

Genmab A\/S<\/strong> (NASDAQ: GMAB<\/a>) announced it will discontinue clinical development of acasunlimab<\/strong>, a PD\u2011L1 x 4\u20111BB bispecific antibody<\/strong> in Phase\u202fIII trials, as part of a strategic portfolio prioritization focusing resources on higher\u2011value programs<\/strong> including EPKINLY, petosemtamab, and Rina\u2011S<\/strong>. The decision follows a thorough assessment of the evolving competitive landscape<\/strong> and will not impact 2025 financial guidance<\/strong>.<\/p>\n\n\n\n

Strategic Decision Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Genmab A\/S (NASDAQ: GMAB)<\/td><\/tr>
Discontinued Asset<\/strong><\/td>Acasunlimab (PD\u2011L1 x 4\u20111BB bispecific antibody)<\/td><\/tr>
Clinical Stage<\/strong><\/td>Phase\u202fIII<\/td><\/tr>
Reason<\/strong><\/td>Strategic focus on highest\u2011impact late\u2011stage opportunities; competitive landscape assessment<\/td><\/tr>
Resources Reallocation<\/strong><\/td>EPKINLY (epcoritamab), petosemtamab, rinatabart sesutecan (Rina\u2011S)<\/td><\/tr>
Financial Impact<\/strong><\/td>No impact on full\u2011year 2025 guidance<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Pipeline Reallocation Strategy<\/h2>\n\n\n\n

Genmab will concentrate capital and R&D resources on its priority late\u2011stage programs<\/strong>:<\/p>\n\n\n\n

Program<\/th>Mechanism<\/th>Indication<\/th>Stage<\/th>Strategic Rationale<\/th><\/tr><\/thead>
EPKINLY (epcoritamab)<\/strong><\/td>CD3 x CD20 T\u2011cell engager<\/td>Lymphoma<\/td>Marketed\/Expanding<\/td>Commercial traction, expansion potential<\/td><\/tr>
Petosemtamab<\/strong><\/td>EGFR x LGR5 bispecific<\/td>Solid tumors<\/td>Late\u2011stage<\/td>Novel target combo, high unmet need<\/td><\/tr>
Rinatabart sesutecan (Rina\u2011S)<\/strong><\/td>FR\u03b1\u2011targeted ADC<\/td>Ovarian cancer<\/td>Late\u2011stage<\/td>Best\u2011in\u2011class ADC potential<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Capital Allocation Framework<\/strong>: The decision aligns with Genmab\u2019s disciplined capital allocation<\/strong>, prioritizing programs with clear differentiation<\/strong> and accelerated path to value creation<\/strong>.<\/p>\n\n\n\n

Competitive Landscape Analysis<\/h2>\n\n\n\n

The PD\u20111\/PD\u2011L1 x 4\u20111BB bispecific space has become increasingly crowded<\/strong>, with multiple competitors advancing similar assets:<\/p>\n\n\n\n

Competitor<\/th>Asset<\/th>Stage<\/th>Differentiation Challenge<\/th><\/tr><\/thead>
Roche<\/strong><\/td>RG6076<\/td>Phase\u202fII<\/td>Established oncology franchise<\/td><\/tr>
Pfizer<\/strong><\/td>PF\u201107209987<\/td>Phase\u202fI<\/td>Deep resources<\/td><\/tr>
AstraZeneca<\/strong><\/td>MEDI5752<\/td>Phase\u202fII<\/td>Combination with Imfinzi<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Genmab\u2019s assessment concluded that acasunlimab\u2019s competitive moat<\/strong> had narrowed, making resource reallocation prudent for shareholder value<\/strong>.<\/p>\n\n\n\n

Financial Implications<\/h2>\n\n\n\n